152 related articles for article (PubMed ID: 28840549)
1. Approaches for Identifying Novel Targets in Precision Medicine: Lessons from DNA Repair.
Williams DT; Staples CJ
Adv Exp Med Biol; 2017; 1007():1-16. PubMed ID: 28840549
[TBL] [Abstract][Full Text] [Related]
2. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
3. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
4. Targeting DNA damage repair precision medicine strategies in cancer.
Brownlie J; Kulkarni S; Algethami M; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
Curr Opin Pharmacol; 2023 Jun; 70():102381. PubMed ID: 37148685
[TBL] [Abstract][Full Text] [Related]
5. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.
Kruse V; Rottey S; De Backer O; Van Belle S; Cocquyt V; Denys H
Acta Clin Belg; 2011; 66(1):2-9. PubMed ID: 21485757
[TBL] [Abstract][Full Text] [Related]
7. Emerging PARP inhibitors for treating breast cancer.
Robert M; Patsouris A; Frenel JS; Gourmelon C; Augereau P; Campone M
Expert Opin Emerg Drugs; 2018 Sep; 23(3):211-221. PubMed ID: 30251552
[TBL] [Abstract][Full Text] [Related]
8. Evolving DNA repair synthetic lethality targets in cancer.
Kulkarni S; Brownlie J; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
Biosci Rep; 2022 Dec; 42(12):. PubMed ID: 36420962
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
Lupo B; Trusolino L
Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
[TBL] [Abstract][Full Text] [Related]
10. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.
Pommier Y; O'Connor MJ; de Bono J
Sci Transl Med; 2016 Oct; 8(362):362ps17. PubMed ID: 27797957
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
Talens F; Jalving M; Gietema JA; Van Vugt MA
Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
[TBL] [Abstract][Full Text] [Related]
12. The DNA Damaging Revolution: PARP Inhibitors and Beyond.
Yap TA; Plummer R; Azad NS; Helleday T
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():185-195. PubMed ID: 31099635
[TBL] [Abstract][Full Text] [Related]
13. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
14. Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis.
Corcoran NM; Clarkson MJ; Stuchbery R; Hovens CM
Clin Cancer Res; 2016 Jul; 22(13):3132-7. PubMed ID: 27169997
[TBL] [Abstract][Full Text] [Related]
15. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
16. PARP Inhibitors in Prostate Cancer.
Ramakrishnan Geethakumari P; Schiewer MJ; Knudsen KE; Kelly WK
Curr Treat Options Oncol; 2017 Jun; 18(6):37. PubMed ID: 28540598
[TBL] [Abstract][Full Text] [Related]
17. Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells.
Trafalis DT; Polonifi A; Dalezis P; Nikoleousakos N; Katsamakas S; Sarli V
Chem Biol Drug Des; 2017 Nov; 90(5):854-866. PubMed ID: 28432813
[TBL] [Abstract][Full Text] [Related]
18. Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.
Palmbos PL; Hussain MH
Oncology (Williston Park); 2016 May; 30(5):377-85. PubMed ID: 27188668
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.
Shah SM; Demidova EV; Lesh RW; Hall MJ; Daly MB; Meyer JE; Edelman MJ; Arora S
Cancer Treat Rev; 2022 Mar; 104():102337. PubMed ID: 35051883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]